Gielenny M. Salem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gielenny M. Salem has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Suan-Sin Foo
Department of Microbial Sciences in Health, Cleveland Clinic, Cleveland, USA
5 shared publications - Karin Nielsen-Saines
Department of Pediatrics, David Geffen UCLA School of Medicine, Los Angeles, USA
3 shared publications Adrian B. Abarientos
Graduate Institute of Microbiology and Public Health, College of Veterinary Medicine, National Chung Hsing University, Taichung City, Taiwan
2 shared publicationsCheng-Sheng Song
Graduate Institute of Microbiology and Public Health, College of Veterinary Medicine, National Chung Hsing University, Taichung City, Taiwan
2 shared publications- Day-Yu Chao
Doctoral Program in Microbial Genomics, National Chung Hsing University and Academia Sinica, Taichung City, Taiwan
2 shared publications Débora Familiar-Macedo
Laboratory of Virus-Host Interactions (LIVH), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz)
2 shared publications
Latest Publications
- 12 November 2026
- Published by American Society for Microbiology in Clinical Microbiology Reviews
Maternal-fetal health in arboviral diseases: clinical outcomes following prenatal dengue and chikungunya virus infections
SUMMARY: Arthropod-borne viruses (arboviruses) are an increasingly important cause of global infectious disease, yet their effects during pregnancy and early life remain incompletely understood. In the context of declining fertility and birth rates globally, infectious threats to successful pregnancy and neonatal health warrant greater attention. Dengue virus (DENV) and chikungunya virus (CHIKV), two of the most prevalent mosquito-borne viruses, are underrecognized contributors to maternal-fetal health. Although these infections rarely result in classical congenital syndromes, accumulating clinical, epidemiological, and experimental evidence indicates that prenatal exposure can impair placental function, drive maternal immune dysregulation, and influence fetal and neonatal immune development. This review summarizes current knowledge on the maternal, placental, and pediatric consequences of DENV and CHIKV infection during pregnancy. We outline the immunological features of the maternal-fetal interface and discuss how pregnancy-associated immune modulation shapes antiviral responses and placental homeostasis. We then review epidemiological and clinical evidence linking prenatal arboviral infection with adverse pregnancy outcomes, neonatal disease, and potential long-term neurodevelopmental effects. Mechanistic insights, including viral immune evasion, placental inflammation, and antibody-mediated immunopathology, are examined. Finally, we discuss clinical considerations for monitoring arboviral-exposed pregnancies and progenies, alongside emerging strategies to reduce maternal infection and improve neonatal outcomes.
- 12 November 2026
- Published by American Society for Microbiology in Clinical Microbiology Reviews
Maternal-fetal health in arboviral diseases: clinical outcomes following prenatal dengue and chikungunya virus infections
SUMMARY: Arthropod-borne viruses (arboviruses) are an increasingly important cause of global infectious disease, yet their effects during pregnancy and early life remain incompletely understood. In the context of declining fertility and birth rates globally, infectious threats to successful pregnancy and neonatal health warrant greater attention. Dengue virus (DENV) and chikungunya virus (CHIKV), two of the most prevalent mosquito-borne viruses, are underrecognized contributors to maternal-fetal health. Although these infections rarely result in classical congenital syndromes, accumulating clinical, epidemiological, and experimental evidence indicates that prenatal exposure can impair placental function, drive maternal immune dysregulation, and influence fetal and neonatal immune development. This review summarizes current knowledge on the maternal, placental, and pediatric consequences of DENV and CHIKV infection during pregnancy. We outline the immunological features of the maternal-fetal interface and discuss how pregnancy-associated immune modulation shapes antiviral responses and placental homeostasis. We then review epidemiological and clinical evidence linking prenatal arboviral infection with adverse pregnancy outcomes, neonatal disease, and potential long-term neurodevelopmental effects. Mechanistic insights, including viral immune evasion, placental inflammation, and antibody-mediated immunopathology, are examined. Finally, we discuss clinical considerations for monitoring arboviral-exposed pregnancies and progenies, alongside emerging strategies to reduce maternal infection and improve neonatal outcomes.
- Open Access
- 25 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Distinct inflammatory marker profiles of adolescents and young adults among the HIV risk, infection, and treatment spectrum
Youth living with or at HIV-risk exhibit distinct immune perturbations during HIV exposure, infection, and antiretroviral therapy (ART). Understanding immune perturbations is critical for development of tailored prevention and enhanced therapeutic strategies. We performed plasma proteomic profiling of 49 biomarkers using Luminex multiplex assay in 262 participants (mean age of 21.9 years), including healthy controls, high-risk youth without HIV (HRY), newly diagnosed youth living with HIV (NY), and previously diagnosed youth on ART for over 24 months (PY), and report distinct immune landscapes. Among HRY, we observe dysregulation of circulating interferon-driven inflammation. NY display overt systemic inflammation at diagnosis, which partially resolves but does not fully normalize within 24 months of ART. PY display largely normalized immune profiles, though circulating signatures consistent with residual checkpoint activation persist. Our results identify conserved and stage-specific, circulating inflammatory modulators and key transcriptional regulators delineating HIV susceptibility, progression, and long-term treatment responses.
- 25 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDistinct inflammatory marker profiles of adolescents and young adults among the HIV risk, infection, and treatment spectrum
Youth living with or at HIV-risk exhibit distinct immune perturbations during HIV exposure, infection, and antiretroviral therapy (ART). Understanding immune perturbations is critical for development of tailored prevention and enhanced therapeutic strategies. We performed plasma proteomic profiling of 49 biomarkers using Luminex multiplex assay in 262 participants (mean age of 21.9 years), including healthy controls, high-risk youth without HIV (HRY), newly diagnosed youth living with HIV (NY), and previously diagnosed youth on ART for over 24 months (PY), and report distinct immune landscapes. Among HRY, we observe dysregulation of circulating interferon-driven inflammation. NY display overt systemic inflammation at diagnosis, which partially resolves but does not fully normalize within 24 months of ART. PY display largely normalized immune profiles, though circulating signatures consistent with residual checkpoint activation persist. Our results identify conserved and stage-specific, circulating inflammatory modulators and key transcriptional regulators delineating HIV susceptibility, progression, and long-term treatment responses.
- Open Access
- 21 April 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Maternal-infant immune signatures in infants at risk for SARS-CoV-2-associated neurodevelopmental disorders
Maternal immune activation during pregnancy has been associated with abnormal infant neurodevelopment. During the COVID-19 pandemic, we enrolled pregnant individuals with laboratory-confirmed SARS-CoV-2 infection into a cohort study conducted in Los Angeles, United States, and Rio de Janeiro, Brazil, and monitored their infants for neurodevelopmental outcomes. We reported a ten-fold higher rate of developmental delay in 172 SARS-CoV-2-exposed children (11.6%) compared to 128 pre-pandemic controls (1.6%) and a nearly 2-fold higher frequency of positive screens for autism spectrum disorder (ASD) in 218 SARS-CoV-2-exposed (10.1%) children as compared to 527 unexposed control children (5.7%) evaluated through standardized developmental tools. To identify potential biomarkers of SARS-CoV-2-associated risk of abnormal infant neurodevelopment, we evaluated the serum immunoprofiles of a subset of mother-infant dyads from this cohort. Serum proteomics profiling of 34 newborns (27 SARS-CoV-2-exposed and 7 controls) revealed 62 biomarkers dysregulated in SARS-CoV-2-exposed children at risk for neurodevelopmental disorders, including activation of nicotinamide biosynthesis, microglial cells, and neutrophil extravasation. Maternal serum profiling of 51 women (33 SARS-CoV-2-positive and 18 controls) identified 34 biomarkers associated with upregulated apoptosis signaling in COVID-19 affected pregnancies. Our findings suggest prenatal SARS-CoV-2 infection is potentially associated with dysregulation of maternal-infant peripheral immunity profiles reportedly associated with neurodevelopmental disorders.
- 21 April 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessMaternal-infant immune signatures in infants at risk for SARS-CoV-2-associated neurodevelopmental disorders
Maternal immune activation during pregnancy has been associated with abnormal infant neurodevelopment. During the COVID-19 pandemic, we enrolled pregnant individuals with laboratory-confirmed SARS-CoV-2 infection into a cohort study conducted in Los Angeles, United States, and Rio de Janeiro, Brazil, and monitored their infants for neurodevelopmental outcomes. We reported a ten-fold higher rate of developmental delay in 172 SARS-CoV-2-exposed children (11.6%) compared to 128 pre-pandemic controls (1.6%) and a nearly 2-fold higher frequency of positive screens for autism spectrum disorder (ASD) in 218 SARS-CoV-2-exposed (10.1%) children as compared to 527 unexposed control children (5.7%) evaluated through standardized developmental tools. To identify potential biomarkers of SARS-CoV-2-associated risk of abnormal infant neurodevelopment, we evaluated the serum immunoprofiles of a subset of mother-infant dyads from this cohort. Serum proteomics profiling of 34 newborns (27 SARS-CoV-2-exposed and 7 controls) revealed 62 biomarkers dysregulated in SARS-CoV-2-exposed children at risk for neurodevelopmental disorders, including activation of nicotinamide biosynthesis, microglial cells, and neutrophil extravasation. Maternal serum profiling of 51 women (33 SARS-CoV-2-positive and 18 controls) identified 34 biomarkers associated with upregulated apoptosis signaling in COVID-19 affected pregnancies. Our findings suggest prenatal SARS-CoV-2 infection is potentially associated with dysregulation of maternal-infant peripheral immunity profiles reportedly associated with neurodevelopmental disorders.
- Open Access
- 10 October 2024
- Published by Springer Nature in The EMBO Journal
- Vol. 43 (22) , 5494-5529
Transplacental SARS-CoV-2 protein ORF8 binds to complement C1q to trigger fetal inflammation
Prenatal SARS-CoV-2 infection is associated with higher rates of pregnancy and birth complications, despite that vertical transmission rates are thought to be low. Here, multi-omics analyses of human placental tissues, cord tissues/plasma, and amniotic fluid from 23 COVID-19 mother-infant pairs revealed robust inflammatory responses in both maternal and fetal compartments. Pronounced expression of complement proteins (C1q, C3, C3b, C4, C5) and inflammatory cytokines (TNF, IL-1α, and IL-17A/E) was detected in the fetal compartment of COVID-19-affected pregnancies. While ~26% of fetal tissues were positive for SARS-CoV-2 RNA, more than 60% of fetal tissues contained SARS-CoV-2 ORF8 proteins, suggesting transplacental transfer of this viral accessory protein. ORF8-positive fetal compartments exhibited increased inflammation and complement activation compared to ORF8-negative COVID-19 pregnancies. In human placental trophoblasts in vitro, exogenous ORF8 exposure resulted in complement activation and inflammatory responses. Co-immunoprecipitation analysis demonstrated that ORF8 binds to C1q specifically by interacting with a 15-peptide region on ORF8 (C37-A51) and the globular domain of C1q subunit A. In conclusion, an ORF8-C1q-dependent complement activation pathway was identified in COVID-19-affected pregnancies, likely contributing to fetal inflammation independently of fetal virus exposure.
- 10 October 2024
- Published by Springer Nature in The EMBO Journal
- Vol. 43 (22) , 5494-5529
Open AccessTransplacental SARS-CoV-2 protein ORF8 binds to complement C1q to trigger fetal inflammation
Prenatal SARS-CoV-2 infection is associated with higher rates of pregnancy and birth complications, despite that vertical transmission rates are thought to be low. Here, multi-omics analyses of human placental tissues, cord tissues/plasma, and amniotic fluid from 23 COVID-19 mother-infant pairs revealed robust inflammatory responses in both maternal and fetal compartments. Pronounced expression of complement proteins (C1q, C3, C3b, C4, C5) and inflammatory cytokines (TNF, IL-1α, and IL-17A/E) was detected in the fetal compartment of COVID-19-affected pregnancies. While ~26% of fetal tissues were positive for SARS-CoV-2 RNA, more than 60% of fetal tissues contained SARS-CoV-2 ORF8 proteins, suggesting transplacental transfer of this viral accessory protein. ORF8-positive fetal compartments exhibited increased inflammation and complement activation compared to ORF8-negative COVID-19 pregnancies. In human placental trophoblasts in vitro, exogenous ORF8 exposure resulted in complement activation and inflammatory responses. Co-immunoprecipitation analysis demonstrated that ORF8 binds to C1q specifically by interacting with a 15-peptide region on ORF8 (C37-A51) and the globular domain of C1q subunit A. In conclusion, an ORF8-C1q-dependent complement activation pathway was identified in COVID-19-affected pregnancies, likely contributing to fetal inflammation independently of fetal virus exposure.
- Open Access
- 17 July 2024
- Published by Elsevier in EBioMedicine
- Vol. 106, 105249
Sustained chronic inflammation and altered childhood vaccine responses in children exposed to Zika virus
- 17 July 2024
- Published by Elsevier in EBioMedicine
- Vol. 106, 105249
Open AccessSustained chronic inflammation and altered childhood vaccine responses in children exposed to Zika virus
- Open Access
- 1 March 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1
Author Correction: Antibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus
- 1 March 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1
Open AccessAuthor Correction: Antibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus
- Open Access
- 24 January 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-21
Antibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus
Exposure to multiple mosquito-borne flaviviruses within a lifetime is not uncommon; however, how sequential exposures to different flaviviruses shape the cross-reactive humoral response against an antigen from a different serocomplex has yet to be explored. Here, we report that dengue-infected individuals initially primed with the Japanese encephalitis virus (JEV) showed broad, highly neutralizing potencies against Zika virus (ZIKV). We also identified a rare class of ZIKV-cross-reactive human monoclonal antibodies with increased somatic hypermutation and broad neutralization against multiple flaviviruses. One huMAb, K8b, binds quaternary epitopes with heavy and light chains separately interacting with overlapping envelope protein dimer units spanning domains I, II, and III through cryo-electron microscopy and structure-based mutagenesis. JEV virus-like particle immunization in mice further confirmed that such cross-reactive antibodies, mainly IgG3 isotype, can be induced and proliferate through heterologous dengue virus (DENV) serotype 2 virus-like particle stimulation. Our findings highlight the role of prior immunity in JEV and DENV in shaping the breadth of humoral response and provide insights for future vaccination strategies in flavivirus-endemic countries.
- 24 January 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-21
Open AccessAntibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus
Exposure to multiple mosquito-borne flaviviruses within a lifetime is not uncommon; however, how sequential exposures to different flaviviruses shape the cross-reactive humoral response against an antigen from a different serocomplex has yet to be explored. Here, we report that dengue-infected individuals initially primed with the Japanese encephalitis virus (JEV) showed broad, highly neutralizing potencies against Zika virus (ZIKV). We also identified a rare class of ZIKV-cross-reactive human monoclonal antibodies with increased somatic hypermutation and broad neutralization against multiple flaviviruses. One huMAb, K8b, binds quaternary epitopes with heavy and light chains separately interacting with overlapping envelope protein dimer units spanning domains I, II, and III through cryo-electron microscopy and structure-based mutagenesis. JEV virus-like particle immunization in mice further confirmed that such cross-reactive antibodies, mainly IgG3 isotype, can be induced and proliferate through heterologous dengue virus (DENV) serotype 2 virus-like particle stimulation. Our findings highlight the role of prior immunity in JEV and DENV in shaping the breadth of humoral response and provide insights for future vaccination strategies in flavivirus-endemic countries.